Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter

Executive Summary

ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment

You may also be interested in...



Amgen As Model For Corporate Governance: CEO Says Ignorance Is No Excuse

CEOs should not be permitted to argue that they are ignorant of ethical deviations within their companies, Amgen CEO Kevin Sharer declared Jan. 14 during the J.P. Morgan health care conference in San Francisco

Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004

Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17

Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004

Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17

Related Content

UsernamePublicRestriction

Register

PS039079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel